Immunic, Inc. (IMUX)
NASDAQ: IMUX · Real-Time Price · USD
14.30
-0.24 (-1.65%)
Aug 7, 2026, 4:00 PM EDT - Market closed
Immunic Employees
Immunic had 95 employees as of March 31, 2026. The number of employees increased by 3 or 3.26% since the number was last reported on December 31, 2025.
Employees
95
Change
3
Growth
3.26%
Revenue / Employee
n/a
Profits / Employee
-$1,097,758
Market Cap
194.79M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Mar 31, 2026 | 95 | 3 | 3.26% |
| Dec 31, 2025 | 92 | 1 | 1.10% |
| Dec 31, 2024 | 91 | 14 | 18.18% |
| Dec 31, 2023 | 77 | 11 | 16.67% |
| Dec 31, 2022 | 66 | 11 | 20.00% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Protalix BioTherapeutics | 226 |
| Humacyte | 184 |
| Coherus Oncology | 145 |
| Tonix Pharmaceuticals Holding | 142 |
| Voyager Therapeutics | 141 |
| Alector | 103 |
| Alpha Cognition | 71 |
| Precision BioSciences | 66 |
IMUX News
- 26 days ago - Immunic Slides: Investor presentation - Filings
- 4 weeks ago - Immunic to Participate in Investor Conferences in July - PRNewsWire
- 2 months ago - Immunic to Participate in Investor, Industry and Scientific Conferences in June - PRNewsWire
- 2 months ago - Immunic Slides: Corporate presentation - Filings
- 2 months ago - Immunic Proxy statement: Proxy filing - Filings
- 2 months ago - Immunic to Present Additional Phase 2 CALLIPER Trial Data for Vidofludimus Calcium at the CMSC Annual Meeting 2026, Reinforcing Its Potential in Progressive Multiple Sclerosis - PRNewsWire
- 2 months ago - Immunic CEO Daniel Vitt to step down, Erik Lundgren to succeed - TheFly
- 2 months ago - Immunic Appoints Distinguished Biopharmaceutical Executive Erik Lundgren as Chief Executive Officer - PRNewsWire